Signatures of Pancreatic Ductal Adenocarcinoma Uncovered by Integrative Multi-Omics Analysis

Background—Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies, with a dismal 5-year survival rate. Despite continuous efforts to study its molecular signatures, the high degree of tumor-associated cellular heterogeneity in PDAC introduces extraneous microenvironmental components that complicate analysis. In recent years, multi-omics approaches have shown promise in deconvoluting cellular composition and enabling more specific, comprehensive cancer profiling. Method—To better characterize PDAC, we analyzed transcriptomic and proteomic data from 140 tumor tissues with 67 paired normal adjacent tissues and single-cell RNA sequencing data from 73 tumor tissues. Results—Using this approach, we successfully attributed molecular signatures to distinct cell-type populations. Overall, we found 59 tumor-cell-derived PDAC molecular signatures and evaluated them for functional relevance, prognostic value, and potential therapeutic implications. Among these, we identified molecular features associated with increased tumorigenic activity and immunosuppression. Moreover, survival analysis of protein phosphorylation and overall expression informed prognostic significance for potential therapeutic targets. Notably, we found that several phosphorylation changes correlate with poor patient survival, suggesting potential paths for therapeutic intervention by targeting protein post-translational modifications. Conclusion—Our study provides a detailed understanding of PDAC by characterizing key tumor-specific signatures that could serve as potential targets to improve clinical outcomes for this disease.